Skip to content

SITC 2023

Event Information:


November 1st to 5th, 2023

San Diego, California

Related Models & Services

CD34+ Humanized Mouse
Immuno-Oncology Models

Advancing Cancer Immunotherapy: Join Us at SITC 2023!

The Society for Immunotherapy of Cancer (SITC) is pleased to announce its 38th Annual Meeting & Pre-Conference Programs (SITC 2023), scheduled to occur from November 1st to 5th, 2023, in the vibrant city of San Diego, CA.

This event will assemble a global network of eminent researchers and industry thought leaders for a lively exchange of the most recent immuno-oncology findings, technological advancements, updates on clinical trials, and introductions to emerging biotechnology companies.

TransCure bioServices is thrilled to join this year’s Congress, where we will be unveiling our research posters that shed light on the use of humanized mice in preclinical immuno-oncology studies. We eagerly anticipate interacting at this dynamic event, connecting with existing and potential collaborators, and staying abreast of the newest developments in gene and cell therapy, and immunotherapies.

The SITC 2023 Congress is a golden opportunity for all attendees to collaborate, exchange innovative concepts and established wisdom, and discuss discoveries in the field.

We invite you to join us at our booth to learn about the latest breakthroughs in cancer immunotherapy and how we can collectively push the boundaries in this vital sector of cancer treatment.

Patrick Nef, Co-Founder, President & CEOPresenting in person for TransCure bioServices:

Patrick Nef, Co-Founder, President & CEO

Patrick holds a PhD from the University of Geneva (Switzerland) and has over 30 years of experience in R&D and early drug development in academia, biotechnology industry, small and large pharmaceuticals and non-for-profit public-private partnership foundation. He co-founded TransCure bioServices SAS in 2012 to develop human immune system mouse models for immuno-oncology, infectious and inflammation diseases. Previously, he served as Chief Business Officer at Medicines for Malaria Venture from 2008 to 2011 to assist their efforts in reducing the burden of malaria in endemic countries by discovering, developing and facilitating delivery of new, effective and affordable antimalarial drugs. He was Chief Scientific Officer at Synosia Therapeutics Inc. from 2006 to 2008 to develop drugs for neuro-degenerative and psychiatric disorders, Chief Executive Officer at Faust Pharmaceutical SA in 2005 to develop CNS drugs and as Global Business Director, and Vice-President & Disease Area Head for CNS at F. Hoffmann-La Roche Ltd. from 1996-2005. Prior to that, he was Assistant Professor in the Biochemistry Department at the University of Geneva, Switzerland from 1992 and has published more than 46 peer-reviewed articles/reviews/patents.

Kiave Ho Wang Yin, PhD, Director of Innovation and Business DevelopmentPresenting in person for TransCure bioServices:

Kiave-Yune Ho Wang Yin, PhD, Director of Innovation and Business Development

Kiave Ho Wang Yin holds a PhD in Immunology/Oncology from the Paris 7 University (France). She worked for 5 years in the Center of Cardiovascular Research (Paris) as scientist in the field of inflammation and angiogenesis. She has published more than 10 papers in peer-reviewed international journals in oncology and inflammation. She is a highly experienced scientist in R&D research and in vivo pharmacology preclinical mouse models and joined the TransCure bioservices in 2016.

Dan Georgess, PhD, Chief Scientific OfficerPresenting in person for TransCure bioServices:

Dan Georgess, PhD, Chief Scientific Officer

Dan is an innovative scientist with extensive international experience in team leadership, research strategy, and interdisciplinary collaboration. He is dedicated to promoting cross-functional efforts to address complex challenges in therapeutics development. Prior to joining TransCure bioServices, Dan was a Marie Curie Ph.D. fellow at ENS de Lyon (France), Suzan G. Komen postdoctoral fellow at the Johns Hopkins School of Medicine (USA), and assistant professor and leader of the Cancer Invasion and Metastasis Cluster at the Lebanese American University (Lebanon). In these roles, he developed cutting-edge in vivo and ex vivo approaches for hematopoiesis, autoimmunity, and cancer research, and co-authored 15 peer-reviewed publications. Since joining TransCure bioServices in 2022, initially as Project Leader then transitioning to Director of the Alliance Management Team and now CSO, Dan’s consistent focus has been to drive successful preclinical development of cell therapies and biologics for TransCure’s clients.

This event has concluded